Evidence map›Paper›PMID 28887905›Full record

ReviewMovement disorders : official journal of the Movement Disorder Society2017

Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.

J A Obeso, M Stamelou, C G Goetz, W Poewe, A E Lang, D Weintraub, D Burn, G M Halliday, E Bezard, S Przedborski and 28 more

Abstract readHistorical ArticleReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Movement disorders : official journal of the Movement Disorder Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 404 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
404citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

404 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Transcranial Temporal Interference Stimulation of the Right Globus Pallidus in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2025
    Trial
  7. Trial
  8. Review
  9. Review
  10. The Therapeutic Potential of Purmorphamine Across Disease Models.Journal of cellular and molecular medicine · 2026
    Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

344 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

J A ObesoHM CINAC, Hospital Universitario HM Puerta del Sur, Mostoles, Madrid, Spain.
M StamelouDepartment of Neurology, Philipps University, Marburg, Germany.ORCID http://orcid.org/0000-0003-1668-9925
C G GoetzDepartment of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.
W PoeweDepartment of Neurology, Medical University Innsbruck, Innsbruck, Austria.
A E LangMorton and Gloria Shulman Movement Disorders Clinic and the Edmond J Safra Program in Parkinson's Disease, Toronto Western Hospital, Toronto, Canada.
D WeintraubDepartment of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
D BurnMedical Sciences, Newcastle University, Newcastle, UK.
G M HallidayBrain and Mind Centre, Sydney Medical School, The University of Sydney, Sydney, Australia.ORCID http://orcid.org/0000-0003-0422-8398
E BezardUniversité de Bordeaux, Institut des Maladies Neurodégénératives, Centre National de la Recherche Scientifique Unité Mixte de Recherche 5293, Institut des Maladies Neurodégénératives, Bordeaux, France.
S PrzedborskiDepartments of Neurology, Pathology, and Cell Biology, the Center for Motor Neuron Biology and Disease, Columbia University, New York, New York, USA.
S LehericyInstitut du Cerveau et de la Moelle épinière - ICM, Centre de NeuroImagerie de Recherche - CENIR, Sorbonne Universités, UPMC Univ Paris 06, Inserm U1127, CNRS UMR 7225, Paris, France.
D J BrooksClinical Sciences Department, Newcastle University, Newcastle, UK.
J C RothwellHuman Neurophysiology, Sobell Department, UCL Institute of Neurology, London, UK.ORCID http://orcid.org/0000-0003-1367-6467
M HallettHuman Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
M R DeLongDepartment of Neurology, Emory University School of Medicine, Atlanta, Georgia, USA.
C MarrasMorton and Gloria Shulman Movement Disorders Centre and the Edmond J Safra Program in Parkinson's disease, Toronto Western Hospital, University of Toronto, Toronto, Canada.
C M TannerMovement Disorders and Neuromodulation Center, Department of Neurology, University of California-San Francisco, San Francisco, California, USA.
G W RossVeterans Affairs Pacific Islands Health Care System, Honolulu, Hawaii, USA.
J W LangstonParkinson's Institute, Sunnyvale, California, USA.
C KleinInstitute of Neurogenetics, University of Luebeck, Luebeck, Germany.
V BonifatiDepartment of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands.
J JankovicParkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas, USA.
A M LozanoDepartment of Neurosurgery, Toronto Western Hospital, University of Toronto, Toronto, Canada.
G DeuschlDepartment of Neurology, Universitätsklinikum Schleswig-Holstein, Christian Albrechts University Kiel, Kiel, Germany.ORCID http://orcid.org/0000-0002-4176-9196
H BergmanDepartment of Medical Neurobiology, Institute of Medical Research Israel-Canada, Jerusalem, Israel.
E TolosaParkinson's Disease and Movement Disorders Unit, Neurology Service, Institut Clínic de Neurociències, Hospital Clínic de Barcelona, Barcelona, Spain.
M Rodriguez-ViolanteMovement Disorders Clinic, Clinical Neurodegenerative Research Unit, Mexico City, Mexico.ORCID http://orcid.org/0000-0002-6041-9941
S FahnDepartment of Neurology, Columbia University Medical Center, New York, New York, USA.
R B PostumaDepartment of Neurology, McGill University, Montreal General Hospital, Montreal, Quebec, Canada.
D BergKlinik für Neurologie, UKSH, Campus Kiel, Christian-Albrechts-Universität, Kiel, Germany.
K MarekInstitute for Neurodegenerative Disorders, New Haven, Connecticut, USA.
D G StandaertDepartment of Neurology, University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID http://orcid.org/0000-0003-2921-8348
D J SurmeierDepartment of Physiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
C W OlanowDepartments of Neurology and Neuroscience, Mount Sinai School of Medicine, New York, New York, USA.
J H KordowerResearch Center for Brain Repair, Rush University Medical Center, Chicago, Illinois, USA.
P CalabresiNeurological Clinic, Department of Medicine, Hospital Santa Maria della Misericordia, University of Perugia, Perugia, Italy.
A H V SchapiraUniversity Department of Clinical Neurosciences, UCL Institute of Neurology, University College London, London, UK.
A J StoesslPacific Parkinson's Research Centre, Division of Neurology & Djavadf Mowafaghian Centre for Brain Health, University of British Columbia, British Columbia, Canada.

Funding

Pathophysiology of Basal Ganglia DisordersZIANS003031 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI HALLETT, MARK · 2009 to 2023
$22.7M
Project IV: "Alpha-Synuclein Strains & Diverse Synucleinopathies"P50NS053488 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI TROJANOWSKI, JOHN Q. · 2007 to 2017
$20.9M
Dopaminergic and Muscarinic Signaling in the StriatumR01NS034696 · NINDS · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI SURMEIER, DALTON JAMES · 1996 to 2018
$4.3M
NINDS NIH HHS P50 NS053488NINDS NIH HHS R01 NS034696
6 · The paper itself

Abstract

This article reviews and summarizes 200 years of Parkinson's disease. It comprises a relevant history of Dr. James Parkinson's himself and what he described accurately and what he missed from today's perspective. Parkinson's disease today is understood as a multietiological condition with uncertain etiopathogenesis. Many advances have occurred regarding pathophysiology and symptomatic treatments, but critically important issues are still pending resolution. Among the latter, the need to modify disease progression is undoubtedly a priority. In sum, this multiple-author article, prepared to commemorate the bicentenary of the shaking palsy, provides a historical state-of-the-art account of what has been achieved, the current situation, and how to progress toward resolving Parkinson's disease. © 2017 International Parkinson and Movement Disorder Society.

Indexed as

Anniversaries and Special EventsHistory, 19th CenturyHistory, 20th CenturyHistory, 21st CenturyHumansParkinson Disease200 years anniversaryParkinson's diseaseShaking Palsy

Identifiers

PMID28887905
PMCPMC5685546

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.